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It is estimated that viruses play a role in 30% to 80% of 
asthma exacerbations. Thus, virus vaccination in patients 
with asthma could play an important role in preventing 
asthma exacerbations and other complications. Inﬂuenza 
is the only agent for which a routine vaccine is currently 
available. This article discusses whether inﬂuenza vac-
cination in patients with asthma, based on the available 
evidence, is justiﬁed. Cost-effectiveness of (inﬂuenza) 
vaccination for patients with asthma is questionable. 
For the other major viruses involved, the present state 
of affairs is described. Although progress is being made, 
a vaccine may be available in the near future only for 
respiratory syncytial virus (RSV). Meanwhile, clinicians 
and patients should aim for an optimal treatment with 
the currently available asthma medication.
Introduction
Worldwide, asthma is one of the major chronic diseases 
and there is evidence its incidence and prevalence is 
still growing [1]. Today asthma is regarded as a chronic 
inflammatory disease of the airways instead of solely 
a reversible airway obstruction. The use of rescue and 
anti-inflammatory medication has altered the prospects 
of asthma patients and has improved their quality of life. 
Thus, most asthma patients can lead a normal life with-
out restrictions. The degree of asthma control achieved 
by patients is an important predictor of the likelihood of 
complications of the disease [2•].
However, upper and lower respiratory infections 
can trigger exacerbations of acute asthma. Most infec-
tions have a viral origin. They play an important role 
in clinical complications of asthma such as dyspnea, 
pneumonia, and respiratory insufficiency, which result 
in loss of quality of life, absenteeism, use of rescue 
medication, use of antibiotics, physician consultation, 
emergency department visits, hospitalization, and some-
times death.
The best way to prevent exacerbations caused by 
infection is vaccination. This review summarizes the 
current evidence on the role of viral vaccination in the 
protection of asthma patients. We searched Medline and 
Google Scholar for relevant articles and reports published 
between 1999 and July 2006 on the current status of 
vaccination in patients with asthma.
The Role of Viruses in Asthma Exacerbations
Viral infections have long been associated with asthma 
exacerbations. Studies in children report varying inci-
dences, suggesting that between 30% and 80% of 
exacerbations are due to a virus [3–6]. For adults data 
on this issue are scarcer, but adults are believed to have 
as many asthma exacerbations linked with viral infec-
tions as children [7,8]. The spectrum of viruses found 
consists of rhinovirus, coronavirus, respiratory syncy-
tial virus (RSV), influenza virus, and an assortment of 
other viruses. Of these, RSV and influenza affect pri-
marily the lower respiratory tract, whereas rhinovirus 
and coronavirus replicate in the upper respiratory tract. 
The mechanism by which these viruses cause asthma 
exacerbations is not yet known precisely. Postulations 
vary from direct infection to indirect induction of 
inflammatory responses [9].
Clinical Impact
In case of complications in patients with asthma, labo-
ratory proof for the presence of virus should preferably 
coincide with symptomatic disease. However, evidence 
for the rate of complications mostly comes from large 
observational studies. In these reports on the impact 
of viruses, laboratory proof is often lacking. Instead, 
extrapolated, partly population-based, incidence rates of 
influenza or influenza-like illness and the occurrence of 
complications are used as a proxy. In these studies, hard 
confirmation of the responsible agent on the individual 
level is not possible [10–13].
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Other studies are often based on selected populations 
with existing symptoms or complications, reflecting only 
the worst of the spectrum of disease caused by acute 
respiratory infections [9,14–17] and thus disregarding 
their often self-limiting nature.
Prevention and Treatment
Although asthma control achieved by asthmatics is an 
important predictor of the likelihood of complications of 
the disease [2•], asthma exacerbations do not respond to 
inhaled steroids nor can they substantially be prevented 
in this way [18,19]. Only the use of oral corticosteroids 
seems to be unmistakably effective [20,21].
The availability of effective vaccines against the key 
viruses involved in asthma exacerbations thus could play 
an important role in its prevention. Below, we will discuss 
the vaccines that are available or may become available in 
the near future [22].
Human rhinoviruses
This species consists of about 100 serotypes and is respon-
sible for the majority of “common colds.” In asthmatics 
human rhinoviruses are responsible for the majority of 
asthma exacerbations and complications of asthma [23].
Prevalent serotypes change from year to year. When 
prevalent, the relative predominance from any serotype 
is not higher than 40%. Due to these circumstances and 
the large number of serotypes, an effective vaccine is not 
expected in the near future [22,24•].
Coronavirus
Coronaviruses have recently been highlighted because of 
a disease outbreak caused by the so-called severe acute 
respiratory syndrome (SARS) coronavirus. In adults with 
asthma, coronaviruses are the second most important 
cause of virally induced exacerbations [7,8]. 
Animal vaccines are being tested. Despite this a vaccine 
for human use will probably not be available in the near 
future [22].
Respiratory syncytial virus
RSV is especially predominant in young childhood and 
causes wheezing in children. In elderly people with asthma, 
RSV also may play an important role [25]. A connection 
has been suggested between bronchiolitis caused by RSV 
infection in childhood and the development of asthma [26].
Against this background, a vaccine for RSV may 
not only prevent exacerbations but may also prevent the 
development of asthma later on. However, in the 1960s 
an experimental vaccine unfortunately had serious 
adverse effects by increasing the clinical symptoms of 
naturally acquired RSV infections. Several other vaccines 
are being tested [27], and despite the initial problems it 
is believed that a vaccine for routine immunization may 
be available within the next decade [22].
Human influenza
The influenza viruses are classified in three genera, labeled 
A, B, and C. Only types A and B cause considerable epi-
demics. Every year influenza viruses change their genome 
partially, which is called an antigenic drift. Because of 
different subtypes and antigenic drift, formerly built-up 
natural immunity or vaccine-initiated immunity will not 
provide protection throughout successive seasons.
There are three types of influenza A virus known 
to have infected humans and to have transmitted from 
human to human: H1N1, H2N2, and H3N2. However, 
water birds carry and are infected with about 15 different 
H-types. Infections can spread from these birds to poultry, 
swine, and other animals living more closely to humans. 
By mixing infections, new subtypes can develop (antigenic 
shift). If a new subtype has the ability to infect humans 
and disseminate, a pandemic could occur. This is an often 
expressed fear in the case of the H5N1 influenza virus.
Influenza is the only lower respiratory tract infection 
in humans for which a vaccine has existed for decades. 
Inactivated vaccines, delivered by subcutaneous or intra-
muscular injection, are widely used for the prevention 
of influenza. The guidelines of most Western countries 
advise to vaccinate patients with asthma [28].
Influenza is one of the common respiratory tract 
infections in humans [29] and according to the World 
Health Organization a yearly public health problem [30]. 
Every year, influenza centers worldwide report influenza 
activity and the occurrence of influenza-like illnesses 
(ILI) as well as data on subsequent health care use. 
But, many viruses can cause ILI and thus a direct rela-
tion between influenza virus and symptomatic disease 
is difficult to determine. In published articles isolated 
serologic incidence rates, rates of ILI, and the occur-
rence of complications are often used as proxy measures 
for influenza-related clinical illness. Confirmation of 
influenza at an individual level is not provided in these 
large observational studies [11,12,31,32]. However, when 
influenza infection is confirmed by laboratory tests as in 
trials or smaller observational studies, the clinical impact 
of influenza seems to be limited [4,6,33,34•,35].
Incidence of influenza varies from place to place 
and from season to season. National and international 
influenza centers and organizations worldwide report 
incidence figures. Usually, these figures are measured 
in an indirect way and relate to excess hospitalizations 
or mortality due to pneumonia and influenza or excess 
health care use. Seasonal incidence figures for ILI of 
20% to 30% are not uncommon. However, symptom-
atic disease should preferably be corroborated by a 
positive laboratory test [36]. Only in children do such 
figures seem to be available for a considerable number of 
years [37]. Based on these data, the average incidence, 
depending on age category, is between 5% and 9.5%. 
The clinical picture is usually described as mild [37]. 
Regarding the fluctuating incidence of ILI reported, 
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it is likely that in adults, the average incidence does 
not exceed these figures. Comparable figures on the 
incidence in asthmatics are even scarcer. The propor-
tion of asthma exacerbations due to influenza reported 
in asthmatic children were 18% and 5% [4,34•]. No 
severe complications (eg, hospitalizations) were found 
in these two studies. 
The effect of influenza vaccination in preventing 
clinical symptoms is a much-debated item. A number of 
reviews indicate that (inactivated) vaccines can have an 
efficacy of 70% in reducing serologically confirmed cases 
of influenza. However, when using symptom-based out-
comes the vaccines showed an efficacy of only about 25% 
[38–40]. Moreover, in case of a mismatch between the 
vaccine composition and the natural virus, efficacy will 
be much lower or absent.
Over the past years, live attenuated vaccines have been 
developed, tested, and used for intranasal administration. 
The less invasive route, of course, is a benefit in admin-
istering the vaccine. Besides, the extra local immune 
response that is activated is a potential benefit. Yet, even 
then there still remains a striking difference between 
efficacy and clinical effectiveness [39]. Currently, animal 
research is being done into the development of vaccines 
that induce broad-spectrum and long-lasting immune 
response, which, if successful, would alter the prospects 
of the current influenza vaccination programs.
In asthmatics, observational studies report varying 
and sometimes even contradictory outcomes [41–43]. But 
clinical efficacy has not been established yet at the high-
est level of evidence. Uncertainty still remains about the 
degree of protection vaccination affords against influenza-
related symptoms such as asthma exacerbations [44••]. In 
a recent study in children with asthma, no positive effect 
of vaccination was found [34•]. However, a distinct effect 
on quality of life in influenza-related episodes in asthmatic 
children was reported [6].
As for side effects and complications, the evidence 
that influenza vaccination is safe and well tolerated is 
extensive [44••].
Cost-effectiveness of Vaccination
Several studies have addressed the cost-effectiveness 
of influenza vaccination. We also identified one cost-
effectiveness study that addressed a hypothetical RSV 
vaccine in elderly people [45]. All cost-effectiveness 
studies are based on a population-wide use of the 
vaccines, for example, in preschool children or elderly 
persons. In all of these studies, the cost-effectiveness 
of influenza vaccination is based on several premises. 
Often the incidence of influenza is approximated by 
that of ILI in epidemic seasons. These figures certainly 
exceed the average incidence of influenza when tak-
ing into account the seasons with low or no influenza 
activity. Other biases may be the target populations 
and the definition used for influenza [46]. In the 
elderly cost-effectiveness is globally accepted [47]. In 
either case, population-wide cost-effectiveness preven-
tive options against influenza for healthy adults 14 to 
60 years old do not seem to be easily achieved, and 
therefore some authors have suggested that the most 
cost-effective option is not to take any action [48]. For 
high-risk patients with chronic respiratory conditions, 
again, in the elderly cost-effectiveness was achieved; 
however, this was not the case for the 18 to 65 years 
age category [49,50]. In children with high-risk condi-
tions the use of influenza vaccination was calculated to 
be cost-effective. However, this study assumed a much 
higher incidence and a far more favorable effectiveness 
of influenza vaccination than described above [50].
Conclusions
The role of virus vaccination in patients with asthma at this 
moment and in the near future seems to be limited (Table 1).
Currently, vaccines are available for routine use 
only for influenza. However, because of a lack of clini-
cal effectiveness, the natural antigenic variations of 
the influenza virus, and the low average incidence of 
influenza, cost-effectiveness in children and adults with 
asthma will not be easily achieved if vaccination has to 
be delivered annually.
As for the other viruses that play an important role in 
the complications of patients with asthma, many hurdles 
remain to be overcome.
For RSV, the first experiences with vaccines were 
a major disappointment. In the case of coronaviruses, 
attention is understandably focused on a vaccine for the 
prevention of SARS. As for rhinoviruses, the major cause 
of asthma exacerbations, because of the amount of sub-
species a vaccine will not be available in the near future.
Table 1. Availability of vaccines and challenges 
Virus Availability of vaccine in time Challenges facing future development 
Rhinovirus Unknown High number of serotypes, low prevalence of dominant serotype
Coronavirus Unknown Development of experimental human vaccines
Respiratory syncytial virus Expected in 5–10 years Serious side effects of ﬁrst experimental vaccines used in children
Inﬂuenza virus Available Direct proof of effectiveness in preventing complications of 
current vaccines in patients with asthma unknown
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Of course other therapies, such as antiviral medication 
or immunoglobulin, are used and are sometimes effective 
in reducing complications. But, the therapeutic use of these 
treatments is limited because they are often expensive and 
should be used only when there is proof of the agent that is 
causing the patient’s symptoms. For prophylactic use their 
cost is a major problem.
Yet, the role of the clinician in patients with asthma 
experiencing the threat of an exacerbation with its com-
plications is clear. An oral corticosteroid can be provided 
and kept on hand by the patient. This permits initiation 
of more prompt and effective treatment than is likely to 
occur when a patient must first go to a physician’s office 
or emergency department, because it can be taken as soon 
as the response to bronchodilator therapy is incomplete 
[21]. Moreover, patients with asthma should be treated 
according to national and international standards. 
Access to and compliance with inhaled corticosteroid 
treatment is an important predictor of the likelihood of 
asthma exacerbations occurring, including those that 
occur during respiratory viral infections [2•].
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